Transmembrane protein 182 (TMEM182)

Transmembrane protein 182 (TMEM182) is a multi-pass membrane protein enriched in skeletal muscle and adipose tissue. It is negatively regulated by the transcription factor MyoD1 and primarily functions as a suppressor of myogenic differentiation and fusion through direct interaction with integrin beta 1 (ITGB1). TMEM182’s inhibitory effect on myogenesis is mechanistically linked to decreased signaling through ITGB1 to the FAK-ERK and FAK-Akt axes, thereby limiting muscle regeneration and growth. Knockout models demonstrate increased muscle mass and accelerated regeneration, substantiating its role as a key modulator of muscle development. TMEM182 is also implicated in cardiac development but primarily restricts differentiation into cardiomyocytes in favor of cardiac fibroblast lineage determination, mediated via disruption of β-catenin signaling. To date, TMEM182 is not known to be targeted by any approved drugs and is under active study for its biological roles.

Other names

Transmembrane protein 182TMEM182UNQ6974/PRO21957FLJ30294GC02P103353GC02P097144

Not applicable—no approved drugs or investigational agents directly target TMEM182. Mechanistically, TMEM182 modulates cell responses via its interaction with integrin beta 1, affecting the FAK-ERK and FAK-Akt signaling pathways during myogenesis.